Fortis Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Fortis Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-45,602	Closed	-$107K	–	342
2018 Q2	$107K	Hold	45,602	–	–	0.06%	146
2018 Q1	$134K	Hold	45,602	–	–	0.07%	100
2017 Q4	$125K	Buy	45,602 +2,570	+6%	+$7.89K	0.08%	114
2017 Q3	$146K	Buy	+43,032	New	+$120K	0.1%	79

Other funds holding PDLI

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Fortis Advisors's PDLI Position: Q3 2018 in Review

Fortis Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q3 2018, closing a stake of 45,602 shares — an estimated $107K sold.

Fortis Advisors first reported a position in PDLI in Q3 2017 and held it in 4 quarters. The position peaked at $146K in Q3 2017. 152 funds tracked by Wall St. Rank hold PDLI as of Q3 2018.

Fortis Advisors reported no remaining PDL BioPharma, Inc. position as of Q3 2018 after selling out during the quarter.
Fortis Advisors sold 45,602 PDL BioPharma, Inc. shares in Q3 2018, an estimated $107K.
Fortis Advisors first reported a position in PDL BioPharma, Inc. in Q3 2017 and held it in 4 quarters.
Fortis Advisors's PDL BioPharma, Inc. position peaked at $146K in Q3 2017.
152 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2018.

Based on Fortis Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.